Jubilant Biosys Limited is delighted to share a momentous achievement stemming from its strategic collaboration with Inipharm, a biopharmaceutical company based in Bellevue, Washington and San Diego, California focused on discovering and developing therapies for severe liver diseases.

Inipharm’s asset, INI-822, an orally-delivered small molecule inhibitor of HSD17B13 for fibrotic liver disease, has achieved a significant milestone by progressing to Phase 1 clinical trials.

Commenting on the development, Mr. Giuliano Perfetti, CEO, Jubilant Biosys Limited, said "Inipharm has successfully advanced this target to Phase 1, and we are excited to be part of this team, contributing to its progress. This accomplishment is a testament to Jubilant’s experience in successfully delivering Integrated Drug Discovery Programs, showcasing the synergy between our profound scientific acumen and our strategic partnership approach”

Jubilant Biosys remains dedicated to delivering comprehensive and cutting-edge Integrated Drug Discovery programs for Biotech and Pharmaceutical companies.

For queries, please contact: bd@jubilantbiosys.com